Neuropacs cleared a new FDA De Novo category rather than fitting into an existing one, becoming the first authorized "Parkinsonian syndrome diagnostic aid" and giving it a regulatory moat competitors would need their own submission to match. Its imaging biomarker is now being positioned alongside molecular tests like CSF alpha-synuclein assays, suggesting a combined-biomarker diagnostic pathway rather than a single-test replacement for existing workups.